

Lorenzo A CalÃ²

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6000763/publications.pdf>

Version: 2024-02-01

251
papers

4,649
citations

109321

35
h-index

144013

57
g-index

252
all docs

252
docs citations

252
times ranked

4601
citing authors

#	ARTICLE	IF	CITATIONS
1	Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2017, 91, 24-33.	5.2	230
2	The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts. <i>Mediators of Inflammation</i> , 2013, 2013, 1-13.	3.0	208
3	Antioxidant effect of l-carnitine and its short chain esters. <i>International Journal of Cardiology</i> , 2006, 107, 54-60.	1.7	143
4	Diabetes Induces p66shc Gene Expression in Human Peripheral Blood Mononuclear Cells: Relationship to Oxidative Stress. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1130-1136.	3.6	126
5	Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. <i>Journal of Hypertension</i> , 2006, 24, 1115-1124.	0.5	122
6	Effect of Aldosterone and Glycyrrhetic Acid on the Protein Expression of PAI-1 and p22phox in Human Mononuclear Leukocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1973-1976.	3.6	110
7	Increased Expression of Regulator of G Protein Signaling-2 (RGS-2) in Bartter's/Gitelman's Syndrome. A Role in the Control of Vascular Tone and Implication for Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4153-4157.	3.6	106
8	Acute effects of moderate dietary protein restriction in patients with idiopathic hypercalciuria and calcium nephrolithiasis. <i>American Journal of Clinical Nutrition</i> , 1999, 69, 267-271.	4.7	101
9	RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. <i>Journal of Hypertension</i> , 2007, 25, 259-264.	0.5	97
10	Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. <i>Journal of Hypertension</i> , 2017, 35, 205-212.	0.5	93
11	Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1413-1419.	0.7	77
12	Oxidative stress " chronic kidney disease " cardiovascular disease: A vicious circle. <i>Life Sciences</i> , 2018, 210, 125-131.	4.3	77
13	Vascular tone control in humans: Insights from studies in Bartter's/Gitelman's syndromes. <i>Kidney International</i> , 2006, 69, 963-966.	5.2	68
14	Monocyte NADPH Oxidase Subunit p22phox and Inducible Hemeoxygenase-1 Gene Expressions Are Increased in Type II Diabetic Patients: Relationship with Oxidative Stress. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1753-1759.	3.6	66
15	Salivary Phosphate-Binding Chewing Gum Reduces Hyperphosphatemia in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 639-644.	6.1	66
16	Oxidative Stress in Kidney Transplant Patients With Calcineurin Inhibitor-Induced Hypertension: Effect of Ramipril. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 40, 625-631.	1.9	65
17	Hyperparathyroidism Can Be Useful in the Identification of Primary Aldosteronism Due To Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2012, 60, 431-436.	2.7	61
18	Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2804-2809.	0.7	55

#	ARTICLE	IF	CITATIONS
19	Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients. <i>Journal of Hypertension</i> , 2014, 32, 331-338.	0.5	55
20	Aldosterone and Refractory Hypertension: A Prospective Cohort Study. <i>American Journal of Hypertension</i> , 2006, 19, 373-379.	2.0	54
21	Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae. <i>Journal of Hypertension</i> , 2014, 32, 2109-2119.	0.5	53
22	Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. <i>Kidney International</i> , 2021, 99, 324-335.	5.2	53
23	ROCK (RhoA/Rho Kinase) in Cardiovascularâ€“Renal Pathophysiology: A Review of New Advancements. <i>Journal of Clinical Medicine</i> , 2020, 9, 1328.	2.4	51
24	Chronic renal failure, end-stage renal disease, and peritoneal dialysis in Gitelman's syndrome. <i>American Journal of Kidney Diseases</i> , 2001, 38, 165-168.	1.9	50
25	Hypomagnesemia and Chondrocalcinosis in Bartterâ€™s and Gitelmanâ€™s Syndrome: Review of the Pathogenetic Mechanisms. <i>American Journal of Nephrology</i> , 2000, 20, 347-350.	3.1	49
26	Increased urinary NO ₂ ⁻ /NO ₃ ⁻ and cyclic guanosine monophosphate levels in patients with bartter's syndrome: Relationship to vascular reactivity. <i>American Journal of Kidney Diseases</i> , 1996, 27, 784-789.	1.9	48
27	Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes ¹ *1See Editorial by Warnock, p. 1197. <i>Kidney International</i> , 2001, 60, 882-889.	5.2	46
28	Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1518-1525.	0.7	46
29	Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. <i>Journal of Hypertension</i> , 2010, 28, 111-118.	0.5	44
30	Clinical Significance of Cytokine Determination in Synovial Fluid. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2002, 39, 63-88.	6.1	43
31	Reduced susceptibility to oxidation of low-density lipoprotein in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). <i>Journal of Hypertension</i> , 1998, 16, 1001-1008.	0.5	42
32	Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. <i>Journal of Hypertension</i> , 2008, 26, 938-945.	0.5	42
33	High angiotensin II state without cardiac remodeling (Bartterâ€™s and Gitelmanâ€™s syndromes): Are angiotensin II type 2 receptors involved?. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 832-836.	3.3	41
34	Oxidative stress and TGFb in kidney- transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. <i>Clinical Nephrology</i> , 2002, 58, 103-110.	0.7	41
35	<p>Potential role of phytochemicals in metabolic syndrome prevention and therapy</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1987-2002.	2.4	38
36	Salivary Phosphate Secretion in Chronic Kidney Disease. , 2008, 18, 87-90.		37

#	ARTICLE	IF	CITATIONS
37	Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients*1. American Journal of Hypertension, 2004, 17, 604-610.	2.0	34
38	Walnuts Reduce Aortic ET-1 mRNA Levels in Hamsters Fed a High-Fat, Atherogenic Diet. Journal of Nutrition, 2006, 136, 428-432.	2.9	34
39	Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials. Nephrology Dialysis Transplantation, 2015, 30, 541-553.	0.7	34
40	Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis. Journal of the American Heart Association, 2016, 5, .	3.7	34
41	Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes. Journal of Hypertension, 2004, 22, 1963-1969.	0.5	33
42	Reduced content of Î± subunit of Gq protein content in monocytes of Bartter and Gitelman syndromes: Relationship with vascular hyporeactivity. Kidney International, 2002, 61, 353-354.	5.2	32
43	Reduced mRNA and Protein Content of Rho Guanine Nucleotide Exchange Factor (RhoGEF) in Bartter's and Gitelman's Syndromes: Relevance for the Pathophysiology of Hypertension. American Journal of Hypertension, 2005, 18, 1200-1205.	2.0	32
44	Genetics and phenotypic heterogeneity of Dent disease: the dark side of the moon. Human Genetics, 2021, 140, 401-421.	3.8	32
45	Effect of epoetin on HO-1 mRNA level and plasma antioxidants in hemodialysis patients. International Journal of Clinical Pharmacology and Therapeutics, 2003, 41, 187-192.	0.6	32
46	Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis - a molecular biological approach. Clinical Nephrology, 2004, 62, 355-361.	0.7	31
47	Phosphate Salivary Secretion in Hemodialysis Patients: Implications for the Treatment of Hyperphosphatemia. Nephron Physiology, 2007, 105, p52-p55.	1.2	30
48	Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients. Clinical Nutrition, 2014, 33, 437-442.	5.0	29
49	ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications. Journal of Nephrology, 2010, 23, 472-7.	2.0	29
50	Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. Clinical Science, 1987, 72, 483-488.	4.3	28
51	Pseudohyperaldosteronism: Pathogenetic Mechanisms. Critical Reviews in Clinical Laboratory Sciences, 2003, 40, 295-335.	6.1	27
52	Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications. Life Sciences, 2016, 148, 80-85.	4.3	27
53	From protein uptake to Dent disease: An overview of the CLCN5 gene. Gene, 2020, 747, 144662.	2.2	27
54	Hemodiafiltration With Online Regeneration of Ultrafiltrate: Effect on Heme-Oxygenase-1 and Inducible Subunit of Nitric Oxide Synthase and Implication for Oxidative Stress and Inflammation. Artificial Organs, 2011, 35, 183-187.	1.9	26

#	ARTICLE	IF	CITATIONS
55	Molecular Biologyâ€Based Assessment of Vitamin Eâ€Coated Dialyzer Effects on Oxidative Stress, Inflammation, and Vascular Remodeling. <i>Artificial Organs</i> , 2011, 35, E33-9.	1.9	26
56	The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 1245-1250.	1.7	26
57	<p>Evaluating Nephrocheck^{Â®} as a Predictive Tool for Acute Kidney Injury</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2020, Volume 13, 85-96.	1.8	26
58	Intracellular Calcium Signalling and Vascular Reactivity in Bartterâ€™s Syndrome. <i>Nephron</i> , 1996, 72, 570-573.	1.8	25
59	Phosphate binders and management of hyperphosphataemia in end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2065-2068.	0.7	25
60	Insulin Signaling, Glucose Metabolism, and the Angiotensin II Signaling System: Studies in Bartter's/Gitelman's syndromes. <i>Diabetes Care</i> , 2006, 29, 469-471.	8.6	25
61	Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?. <i>PLoS ONE</i> , 2018, 13, e0204618.	2.5	24
62	Heme oxygenase-1 is an important modulator in limiting glucose-induced apoptosis in human umbilical vein endothelial cells. <i>Life Sciences</i> , 2008, 82, 383-392.	4.3	23
63	Control of Vascular Tone in the Syndromes of Bartter and Gitelman. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2000, 37, 503-522.	6.1	22
64	Carnitine-mediated improved response to erythropoietin involves induction of haem oxygenase-1: studies in humans and in an animal model. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 890-895.	0.7	22
65	Salivary Glands: A New Player in Phosphorus Metabolism. , 2011, 21, 39-42.		22
66	Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. <i>Hypertension Research</i> , 2011, 34, 1017-1022.	2.7	22
67	Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies. <i>Current Vascular Pharmacology</i> , 2011, 9, 763-769.	1.7	22
68	Angiotensin II Signalling in Bartter's and Gitelman's Syndromes. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 17-26.	2.2	21
69	A Role for Heme Oxygenase-1 in the Antioxidant and Antiapoptotic Effects of Erythropoietin: The Start of a Good News/Bad News Story?. <i>Nephron Physiology</i> , 2006, 103, 107-111.	1.2	21
70	Salivary Phosphorus and Phosphate Content of Beverages: Implications for the Treatment of Uremic Hyperphosphatemia. , 2009, 19, 69-72.		21
71	Oxidative stress-related proteins in a Connâ€™s adenoma tissue. Relevance for aldosteroneâ€™s prooxidative and proinflammatory activity. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 48-53.	3.3	21
72	Bartterâ€™s and Gitelmanâ€™s diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 637-648.	3.3	21

#	ARTICLE	IF	CITATIONS
73	Long-Term Proton Pump Inhibitor Use is Associated with Vascular Calcification in Chronic Kidney Disease: A Cross-Sectional Study Using Propensity Score Analysis. <i>Drug Safety</i> , 2013, 36, 635-642.	3.2	21
74	Synthesis and catabolism of PGE2 by a nephroblastoma associated with hypercalcemia without bone metastases. <i>Cancer</i> , 1984, 54, 635-637.	4.1	20
75	Effect of olmesartan on oxidative stress in hypertensive patients. Mechanistic support to clinical trials derived evidence. <i>Blood Pressure</i> , 2011, 20, 376-382.	1.5	20
76	<sc>L</sc> carnitine in hemodialysis patients. <i>Hemodialysis International</i> , 2012, 16, 428-434.	0.9	20
77	SIRT1, heme oxygenase-1 and NO-mediated vasodilation in a human model of endogenous angiotensin II type 1 receptor antagonism: implications for hypertension. <i>Hypertension Research</i> , 2013, 36, 873-878.	2.7	20
78	Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 711-716.	3.3	18
79	Arterial hypertension and cardiovascular risk in HIV-infected patients. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 553-558.	1.5	17
80	Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients. <i>Journal of Hypertension</i> , 2014, 32, 193-199.	0.5	17
81	Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?. <i>Journal of Clinical Medicine</i> , 2018, 7, 409.	2.4	17
82	The Pivotal Role of Oxidative Stress in the Pathophysiology of Cardiovascular-Renal Remodeling in Kidney Disease. <i>Antioxidants</i> , 2021, 10, 1041.	5.1	17
83	Early markers of inflammation in a high angiotensin II state—results of studies in Bartter's/Gitelman's syndromes. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1697-1701.	0.7	16
84	High phosphate content beverages in dialysis patients: Relevance for hyperphosphatemia and cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, e39-e40.	2.6	16
85	RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients. <i>Journal of Hypertension</i> , 2010, 28, 1104-1108.	0.5	16
86	Gitelman's syndrome and pregnancy: new potential pathophysiological influencing factors, therapeutic approach and materno-fetal outcome. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1511-1513.	1.5	16
87	Pathophysiology of Post Transplant Hypertension in Kidney Transplant: Focus on Calcineurin Inhibitors Induced Oxidative Stress and Renal Sodium Retention and Implications with RhoA/Rho Kinase Pathway. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 676-685.	2.0	16
88	Factors predicting influenza vaccination adherence among patients in dialysis: an Italian survey. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2434-2439.	3.3	16
89	Systolic and diastolic short-term blood pressure variability and its determinants in patients with controlled and uncontrolled hypertension: A retrospective cohort study. <i>Blood Pressure</i> , 2015, 24, 124-129.	1.5	15
90	The Time has Come for Systematic Screening for Primary Aldosteronism in All Hypertensives —. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1821-1823.	2.8	15

#	ARTICLE	IF	CITATIONS
91	A Continuous Renal Replacement Therapy Protocol for Patients with Acute Kidney Injury in Intensive Care Unit with COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 1529.	2.4	15
92	Kidney transplant in Gitelman's syndrome. Report of the first case. <i>Journal of Nephrology</i> , 2003, 16, 144-7.	2.0	15
93	Increased RBP4 in a human model of activated anti-atherosclerotic and antiremodelling defences. <i>European Journal of Clinical Investigation</i> , 2014, 44, 567-572.	3.4	14
94	In Patients with Chronic Kidney Disease Short Term Blood Pressure Variability is Associated with the Presence and Severity of Sleep Disorders. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 804-815.	2.0	14
95	Is hydrochlorothiazide-induced hypocalciuria due to inhibition of prostaglandin E2 synthesis?. <i>Clinical Science</i> , 1990, 78, 321-325.	4.3	13
96	Peritoneal Sclerosis: Role of Plasticizers in Stimulating Interleukin-1 Production. <i>Peritoneal Dialysis International</i> , 1993, 13, 517-519.	2.3	13
97	Endothelium-Derived Vasoactive Substances in Bartter's Syndrome. <i>Angiology</i> , 1995, 46, 905-913.	1.8	13
98	Effect of Manidipine on Gene Expression and Protein Level of Oxidative Stress-Related Proteins: p22phox and HO-1. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 531-538.	1.9	13
99	Blood pressure in acute ischemic stroke and mortality: a study with noninvasive blood pressure monitoring. <i>Blood Pressure Monitoring</i> , 2006, 11, 199-205.	0.8	13
100	Calcitonin gene-related peptide, heme oxygenase-1, endothelial progenitor cells and nitric oxide-dependent vasodilation relationships in a human model of angiotensin II type-1 receptor antagonism. <i>Journal of Hypertension</i> , 2012, 30, 1406-1413.	0.5	13
101	Bartter/Gitelman syndromes as a model to study systemic oxidative stress in humans. <i>Free Radical Biology and Medicine</i> , 2015, 88, 51-58.	2.9	13
102	Regulation of glomerular filtration in essential hypertension: role of abnormal Na ⁺ transport and atrial natriuretic peptide. <i>Journal of Nephrology</i> , 2002, 15, 489-96.	2.0	13
103	Does p63RhoGEF, a new key mediator of angiotensin II signalling, play a role in blood pressure regulation and cardiovascular remodelling in humans?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 634-636.	1.7	12
104	Daily green tea extract supplementation reduces prothrombotic and inflammatory states in dialysis patients. <i>Journal of Functional Foods</i> , 2013, 5, 1366-1371.	3.4	12
105	Apparent mineralocorticoid excess syndrome, an often forgotten or unrecognized cause of hypokalemia and hypertension: Case report and appraisal of the pathophysiology. <i>Blood Pressure</i> , 2014, 23, 189-192.	1.5	12
106	Constitutive Endothelial Nitric Oxide Synthase (ecNOS) Gene Expression in Human Monocytes. <i>Angiology</i> , 1998, 49, 419-422.	1.8	11
107	Treatment with Calcimimetic (Cinacalcet) Alters Epoetin Dosage Requirements in Dialysis Patients: Preliminary Report. <i>Renal Failure</i> , 2011, 33, 732-735.	2.1	11
108	Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 577-578.	3.7	11

#	ARTICLE	IF	CITATIONS
109	Oxidative stress, inflammation, and peritoneal dialysis: A molecular biology approach. <i>Artificial Organs</i> , 2021, 45, 1202-1207.	1.9	11
110	Giovan Battista Morgagni, a Pioneer of Clinical Nephrology. <i>American Journal of Nephrology</i> , 1999, 19, 222-225.	3.1	10
111	Effect of Doxazosin on Oxidative Stress-Related Proteins in Benign Prostatic Hyperplasia. <i>Urologia Internationalis</i> , 2006, 76, 36-41.	1.3	10
112	Phosphate Content of Beverages in Addition to Food Phosphate Additives: Real and Insidious Danger for Renal Patients. , 2012, 22, 292-293.		10
113	Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 215-223.	2.2	10
114	Cornea verticillata in Fabry disease: a comparative study between slit-lamp examination and in vivo corneal confocal microscopy. <i>British Journal of Ophthalmology</i> , 2020, 104, 718-722.	3.9	10
115	Inhibition of furosemide-sensitive cation transport and activation of sodium-lithium exchange by endogenous circulating factor(s) in Bartter's and Gitelman's syndromes. <i>Journal of Hypertension</i> , 1997, 15, 1407-1413.	0.5	9
116	Oxidative stress and post-transplant hypertension in pediatric kidney-transplanted patients. <i>Journal of Pediatrics</i> , 2006, 149, 53-57.	1.8	9
117	Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients. <i>Pharmacological Research</i> , 2020, 158, 104903.	7.1	9
118	ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes. <i>Frontiers in Medicine</i> , 2021, 8, 647319.	2.6	9
119	Warm Hepatic Ischemia in Pigs: Effects of L-Arginine and Oligotide Treatment. <i>Journal of Investigative Surgery</i> , 2001, 14, 303-312.	1.3	8
120	Hermann Boerhaave and Lithotomy: What He Thought about It. <i>American Journal of Nephrology</i> , 2002, 22, 290-294.	3.1	8
121	Autonomic Nervous System Function in Chronic Hypotension Associated With Bartter and Gitelman Syndromes. <i>American Journal of Kidney Diseases</i> , 2007, 49, 330-335.	1.9	8
122	HO-1 Attenuates Hypertension-Induced Inflammation/Oxidative Stress: Support From Bartter's/Gitelman's Patients. <i>American Journal of Hypertension</i> , 2010, 23, 936-936.	2.0	8
123	Could nutritional therapy take us further in our approaches to Fabry disease?. <i>Nutrition</i> , 2020, 72, 110664.	2.4	8
124	Myocardial function in Bartter's and Gitelman's syndromes. <i>Kidney International</i> , 2003, 64, 366-367.	5.2	7
125	NADPH oxidase, superoxide overproduction and nitric oxide bioavailability in essential hypertension. <i>Journal of Hypertension</i> , 2005, 23, 665-666.	0.5	7
126	Rho/Rho-kinase and C-reactive protein relationship in hypertension and atherosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1131-1132.	0.7	7

#	ARTICLE	IF	CITATIONS
127	Reduction of Hyperphosphatemia is Related with the Reduction of C-Reactive Protein in Dialysis Patients. Study in Sevelamer-Resistant Dialysis Patients Treated with Chitosan Chewing Gum as Salivary Phosphate Binder. <i>Renal Failure</i> , 2011, 33, 11-14.	2.1	7
128	Ultrafiltration for the treatment of congestion: a window into the lung for a better caress to the heart. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1335-1341.	0.7	7
129	Ultrasound for the Clinical Management of Vascular Access Cannulation and Needle Position in Hemodialysis Patients. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 455-459.	1.5	7
130	Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093458.	3.2	7
131	Rho Kinase Activity, Connexin 40, and Atrial Fibrillation: Mechanistic Insights from End-Stage Renal Disease on Dialysis Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 165.	2.4	7
132	Identification of the mineralocorticoid receptor in human spermatozoa. <i>International Journal of Molecular Medicine</i> , 2006, 18, 649-52.	4.0	7
133	Impaired ACE2 glycosylation and protease activity lowers COVID-19 susceptibility in Gitelman's and Bartter's syndromes. <i>Journal of Internal Medicine</i> , 2022, 291, 522-524.	6.0	7
134	Urinary NO ₂ and NO ₃ evaluation by an ion chromatography system. <i>Biomedical Chromatography</i> , 1998, 12, 97-98.	1.7	6
135	The search for a link between inflammation and hypertension—contribution from Bartter's/Gitelman's syndromes. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2340-2342.	0.7	6
136	The association of systemic oxidative stress with insulin resistance: mechanistic insights from studies in Bartter's and Gitelman's syndromes. <i>Clinical Endocrinology</i> , 2015, 83, 994-995.	2.4	6
137	Assessing the Relationship of Angiotensin II Type 1 Receptors with Erythropoietin in a Human Model of Endogenous Angiotensin II Type 1 Receptor Antagonism. <i>CardioRenal Medicine</i> , 2016, 6, 16-24.	1.9	6
138	Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their Enotype?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5660.	4.1	6
139	Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance. <i>Pharmaceuticals</i> , 2021, 14, 279.	3.8	6
140	Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients. <i>Current Vascular Pharmacology</i> , 2018, 16, 603-609.	1.7	6
141	The Effect of Green Tea as an Adjuvant to Enzyme Replacement Therapy on Oxidative Stress in Fabry Disease: A Pilot Study. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	6
142	Is exercise becoming a danger for our health? The complex relationship between exercise and atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 621-623.	1.8	5
143	Angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers and risk of COVID 19: information from Bartter's and Gitelman's syndromes patients. <i>Journal of Hypertension</i> , 2020, 38, 1386.	0.5	5
144	High Blood Pressure Is Associated with Tubulointerstitial Damage along with Glomerular Damage in Glomerulonephritis. A large Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1656.	2.4	5

#	ARTICLE	IF	CITATIONS
145	Switching to HFR Supra resolved refractory itch and quality of life in a chronic dialysis with liver transplant patient. <i>Artificial Organs</i> , 2021, 45, 320-321.	1.9	5
146	Genotype-phenotype correlation in Gordon's syndrome: report of two cases carrying novel heterozygous mutations. <i>Journal of Nephrology</i> , 2022, 35, 859-862.	2.0	5
147	Tracing angiotensin II's yin-yang effects on cardiovascular-renal pathophysiology. <i>Minerva Medica</i> , 2023, 114, .	0.9	5
148	Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2474-2486.	0.7	5
149	Bartter's and Gitelman's syndromes: a confirm in humans of the utility of Rho kinase inhibition for cardiovascular protection. <i>Journal of Hypertension</i> , 2005, 23, 1273-1275.	0.5	4
150	l-Carnitine and erythropoiesis: relationship with haeme oxygenase-1. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1769-1770.	0.7	4
151	Aldosterone, Inflammation, and Preeclampsia. <i>Hypertension</i> , 2005, 45, e10.	2.7	4
152	Rho Kinase Inhibition and Vascular Protection: Support From Studies in Bartter and Gitelman Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, e34; author reply e34-5.	2.4	4
153	NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2402-2402.	0.7	4
154	Aldosterone-induced oxidative stress. <i>Journal of Hypertension</i> , 2014, 32, 2280-2281.	0.5	4
155	Uric acid and cardiovascular-renal disease risk. Insights from a human model opposite to hypertension. <i>International Journal of Cardiology</i> , 2016, 212, 18-19.	1.7	4
156	G12q/p63RhoGEF interaction in RhoA/Rho kinase signaling: investigation in Gitelman's syndrome and implications with hypertension. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 351-356.	3.3	4
157	Gitelman's Syndrome: characterization of a novel c.1181G>A point mutation and functional classification of the known mutations. <i>Hypertension Research</i> , 2018, 41, 578-588.	2.7	4
158	Smoking causes atrial fibrillation? Further evidence on a debated issue. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1434-1436.	1.8	4
159	Licorice from antiquity to the end of the 19th century: applications in medical therapy. <i>Journal of Nephrology</i> , 2004, 17, 337-41.	2.0	4
160	The counter-regulatory arm of the renin-angiotensin system and COVID-19: insights from Gitelman's and Bartter's syndromes. <i>Journal of Hypertension</i> , 2022, 40, 648-649.	0.5	4
161	Physiological relevance of nitric oxide-angiotensin II interplay in the cardiovascular system. <i>Journal of Hypertension</i> , 2000, 18, 351-352.	0.5	3
162	Idiopathic hypercalciuria: O ₂ and NO relationship and altered bone metabolism. <i>Journal of Endocrinological Investigation</i> , 2000, 23, 78-83.	3.3	3

#	ARTICLE	IF	CITATIONS
163	Number and function of circulating endothelial progenitor cells and calcitonin gene-related peptide in hypertension: support from and opportunities in Bartter's and Gitelman's syndromes patients. <i>Journal of Hypertension</i> , 2010, 28, 2169-2170.	0.5	3
164	A very unusual case of hypokalaemia. CKJ: <i>Clinical Kidney Journal</i> , 2013, 6, 87-89.	2.9	3
165	Hemodiafiltration and reduction of inflammation in dialysis patients. <i>Kidney International</i> , 2014, 86, 651.	5.2	3
166	Intensive Home Hemodialysis: An Eye at the Past Looking for the Hemodialysis of the Future. <i>Artificial Organs</i> , 2015, 39, 736-740.	1.9	3
167	To reconsider (limit) the use of phosphate based food and beverages additives. A real need for health preservation. <i>Clinical Nutrition</i> , 2016, 35, 240.	5.0	3
168	Assessment of the Quantitative Value Usefulness of the Aldosterone-Renin Ratio (ARR) for Primary Aldosteronism (AQUARR) Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 19-23.	2.2	3
169	Regional citrate anticoagulation dose for continuous renal replacement therapy. <i>Nephrology</i> , 2020, 25, 361-361.	1.6	3
170	The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelman's and Bartter's Syndromes. <i>Nutrients</i> , 2021, 13, 2960.	4.1	3
171	Impact of different hemodiafiltration solutions on ionemia in long-term CRRT. <i>International Journal of Artificial Organs</i> , 2021, 44, 807-815.	1.4	3
172	Far di Necessità Virtù ¹ , using rare tubulopathies, Gitelman's and Bartter's syndromes, to inform the fight against COVID-19. <i>Journal of Nephrology</i> , 2021, 34, 281-283.	2.0	3
173	The Dialyzer Identification Code (DIC): A filter characteristics codification for dialyzer choice in renal replacement therapy. <i>Artificial Organs</i> , 2020, 44, 1220-1223.	1.9	3
174	Heme oxygenase-1 in type 2 diabetes: from cell first-line defense to early marker of diabetic nephropathy. <i>Minerva Medica</i> , 2016, 107, 123-4.	0.9	3
175	De Lapidibus podagra et chiragra in humano corpore productis (Rome, 1699): the contribution of Giovanni Battista Contoli to the description and classification of urinary tract stones. <i>Journal of Nephrology</i> , 2013, 26, 136-138.	2.0	3
176	Arachidonic acid metabolites in a nephroblastoma associated with paraneoplastic hypercalcemia. <i>Prostaglandins</i> , 1986, 32, 116-120.	1.2	2
177	Water and Its Effects when Drunk Cold. <i>American Journal of Nephrology</i> , 1999, 19, 182-184.	3.1	2
178	Analysis of Gq protein alpha subunit mRNA expression in human monocytes: relevance of the purification step. <i>Clinica Chimica Acta</i> , 2001, 309, 13-18.	1.1	2
179	Salivary Glands: A 'Third Kidney' for Phosphate Excretion in Kidney Disease?. <i>Blood Purification</i> , 2009, 28, 364-364.	1.8	2
180	L-CARNITINE, INFLAMMATION AND HYPERTENSION. <i>Nephrology</i> , 2009, 14, 264-265.	1.6	2

#	ARTICLE	IF	CITATIONS
181	Comment on:Acute kidney injury and rhabdomyolysis: a role for the regulator of G-protein signaling (RGS)-2. <i>Renal Failure</i> , 2010, 32, 529-530.	2.1	2
182	PLC β 1-SHP-2 complex, PLC β 1 tyrosine dephosphorylation and SHP-2 phosphatase activity: a new part of Angiotensin II signaling?. <i>Journal of Biomedical Science</i> , 2011, 18, 38.	7.0	2
183	Dissociating angiotensin 1-9 anticonvulsant remodeling effects from those on blood pressure. <i>Journal of Hypertension</i> , 2014, 32, 1718-1719.	0.5	2
184	Magnesium, cardiovascular renal disease and the Gitelman's syndrome paradox. <i>Journal of Hypertension</i> , 2017, 35, 1122-1124.	0.5	2
185	Proinflammatory/profibrotic effects of aldosterone in Gitelman's syndrome, a human model opposite to hypertension. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 521-526.	3.3	2
186	ACE2 and prognosis of COVID-19: Insights from Bartter's and Gitelman's syndromes patients. <i>Journal of Medical Virology</i> , 2020, 92, 2308-2309.	5.0	2
187	Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 642-647.	0.9	2
188	Going to war with COVID-19: Strategies for SARS-CoV-2 management in the Padua Nephrology and Dialysis Unit's hemodialysis facility. <i>Clinical Nephrology</i> , 2021, 95, 151-156.	0.7	2
189	Rare genetic tubulopathies Gitelman's and Bartter's syndromes and their naturally occurring protection from COVID-19. <i>Minerva Medica</i> , 2022, , .	0.9	2
190	Morbus dominorum: gout as the disease of lords. <i>Journal of Nephrology</i> , 2013, 26, 113-116.	2.0	2
191	On Progress in the History of Nephrology. <i>American Journal of Nephrology</i> , 1999, 19, 99-100.	3.1	1
192	G-Protein β 3-Subunit Gene C825T Polymorphism and Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2004, 11, 107-112.	2.2	1
193	CARNITINE'S PROTECTIVE EFFECT ON OXIDATIVE STRESS IS MEDIATED BY HEME OXYGENASE-1. <i>Nephrology</i> , 2006, 11, 569-569.	1.6	1
194	"The Heart Never Grows Better by AGE"; I Fear Rather Worse...". <i>Blood Purification</i> , 2006, 24, 367-368.	3.67	1
195	Blood Pressure Response After an Acute Stroke During Ambulatory Blood Pressure Monitoring. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 49-50.	2.2	1
196	A pheochromocytoma with normal clonidine-suppression test: how difficult the biochemical diagnosis?. <i>Internal and Emergency Medicine</i> , 2008, 3, 61-64.	2.0	1
197	EPO induces rise in serum ADMA but does not prevent the increase in NO release: the likely involvement of HO-1. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3035-3036.	0.7	1
198	Obsessive-Compulsive and Post Traumatic Avoidance Symptoms Influence the Response to Antihypertensive Therapy: Relevance in Uncontrolled Hypertension. <i>Pharmaceuticals</i> , 2009, 2, 82-93.	3.8	1

#	ARTICLE	IF	CITATIONS
199	Research update for articles published in EJCI in 2008. European Journal of Clinical Investigation, 2010, 40, 770-789.	3.4	1
200	EPO and HO-1 in cardiovascular and renal protection: just a common signaling pathway or a mechanistic link?. Nephrology Dialysis Transplantation, 2011, 26, 3416-3417.	0.7	1
201	Pelvic ureteric junction obstruction and hypertension with target organ damage: A case report and review of the literature. Blood Pressure, 2013, 22, 336-339.	1.5	1
202	Revascularization for atherosclerotic renal artery stenosis: another flawed son of the ASTRAL Study. Hypertension Research, 2013, 36, 85-86.	2.7	1
203	Angiotensin II type 1 and type 2 receptor interplay in hypertension. Journal of Hypertension, 2013, 31, 1055-1056.	0.5	1
204	Angiotensin II Type 2 Receptor Effects: Lesson From a Human Model of Vascular Hyporeactivity. Letter Regarding Kemp et al. Circulation Research, 2014, 115, e24-5.	4.5	1
205	Is there an increased heme oxygenase-1 behind the antioxidant effects of green tea on blood pressure and sympathoexcitation reduction?. Journal of Hypertension, 2017, 35, 1718-1719.	0.5	1
206	New insights on the renal protective effects of mineralocorticoid receptor antagonists. Journal of Hypertension, 2019, 37, 9-10.	0.5	1
207	Rho kinase activity and atrial fibrillation. Journal of Hypertension, 2019, 37, 1096-1097.	0.5	1
208	Relationship between NOX4 level and angiotensin II signaling in Gitelman's syndrome. Implications with hypertension. International Journal of Clinical and Experimental Medicine, 2015, 8, 7487-96.	1.3	1
209	Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach. Journal of Clinical Medicine, 2022, 11, 402.	2.4	1
210	Rho kinase, oxidative stress, ACE2/Ang 1-7 and lung fibrosis. Minerva Medica, 2015, 106, 182-3.	0.9	1
211	In vitro use of standard fluid infusion central venous catheter for slow continuous ultrafiltration feasibility assessment. Artificial Organs, 2022, , .	1.9	1
212	Regulator of G protein signaling ² and control of vascular tone in bartter's/gitelman's syndrome. American Journal of Hypertension, 2004, 17, S153-S154.	2.0	0
213	Oxidative stress and profibrotic action of aldosterone. American Journal of Hypertension, 2005, 18, 441-441.	2.0	0
214	Aldosterone and Resistant Hypertension. Current Hypertension Reviews, 2007, 3, 143-147.	0.9	0
215	A rare cause of flank pain. CKJ: Clinical Kidney Journal, 2010, 3, 316-317.	2.9	0
216	Comment on: Hemodiafiltration in a critical dialysis patient with H1N1 influenza A. Renal Failure, 2010, 32, 902-902.	2.1	0

#	ARTICLE	IF	CITATIONS
217	The PGC1 α -PPAR α -HO-1 system: supporting evidence from studies in Bartter's/Gitelman's syndromes. <i>Cardiovascular Research</i> , 2010, 86, 535-535.	3.8	0
218	Antihypertensive and antiremodeling effects of Rho kinase inhibition via activation of ACE2 pathway. <i>Journal of Hypertension</i> , 2011, 29, 1660-1661.	0.5	0
219	Treatment with Vitamin E-coated membrane dialysers and cardiovascular protection in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1754-1754.	0.7	0
220	Angiotensin II type 2 receptors mediating both vasoconstriction and vasodilation in humans. <i>Journal of Hypertension</i> , 2012, 30, 628-629.	0.5	0
221	Magnesium and Gitelman's Syndrome – a paradox awaiting resolution. <i>Magnesium Research</i> , 2012, 25, 147-148.	0.5	0
222	Of coronary arteries and men: the fight of a dialysis patient against his coronary arteries. <i>Renal Failure</i> , 2014, 36, 627-630.	2.1	0
223	Hypokalemia in Thyrotoxic Periodic Paralysis: Implication for Nephrology Practice. <i>Blood Purification</i> , 2014, 37, 188-188.	1.8	0
224	Hypomagnesaemia, cardiovascular renal negative effects and Gitelman's syndrome: A paradox awaiting resolution. <i>International Journal of Cardiology</i> , 2015, 198, 106-107.	1.7	0
225	Thymoma-associated renal pathology: Is renal biopsy always necessary? A clinical problem-solving exercise and teaching example for physicians. <i>International Urology and Nephrology</i> , 2017, 49, 1893-1895.	1.4	0
226	SPO21CARDIOVASCULAR-RENAL REMODELING IN FABRY DISEASE: POSSIBLE INVOLVEMENT OF OXIDATIVE STRESS. A MOLECULAR BIOLOGY APPROACH. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i354-i354.	0.7	0
227	A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma. <i>Nephrology</i> , 2018, 23, 1065-1067.	1.6	0
228	Bartter and Gitelman Syndromes. , 2019, , 713-721.		0
229	P1190OXIDATIVE STRESS AND INFLAMMATION IN PERITONEAL DIALYSIS: DANGEROUS AND TO BE SOLVED. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
230	Two unusual cases of Gitelman's syndrome with a complex inheritance: how the phenotype can help interpret the genotype: lesson for the clinical nephrologist. <i>Journal of Nephrology</i> , 2021, 34, 1327-1330.	2.0	0
231	P0084DIGENIC INHERITANCE: TWO RARE CASES OF GITELMAN SYNDROME. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
232	On the imbalanced protective arm of RAS in COVID-19: Lesson from rare genetic tubulopathies. <i>International Journal of Clinical Practice</i> , 2021, 75, e14075.	1.7	0
233	M0073HISTOLOGICAL PREDICTORS OF PROTEINURIA AND RENAL OUTCOMES IN PRIMARY MEMBRANOUS NEPHROPATHY: IS INTERSTITIAL FIBROSIS THE MAIN CHARACTER?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
234	M0022EVALUATION OF THE EFFECT OF TOLVAPTAN ON OXIDATIVE STRESS IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0

#	ARTICLE	IF	CITATIONS
235	MO012: ACE2 AND SARS-COV-2 INFECTION RISK: INSIGHTS FROM PATIENTS WITH TWO RARE GENETIC TUBULOPATHIES, GITELMAN'S AND BARTTER'S SYNDROMES. <i>Nephrology Dialysis Transplantation</i> , 2021, 36(7), .		0
236	Light chain deposition disease with low glomerular proteinuria and multiple myeloma: If you search you find. <i>Nephrology</i> , 2021, 26, 842-843.	1.6	0
237	Padova University nephrology unit's peritoneal dialysis management during the COVID-19 pandemic. <i>Clinical Nephrology</i> , 2021, 96, 60-62.	0.7	0
238	Aldosterone-mediated endothelial remodeling and oxidative stress. <i>Kidney International</i> , 2005, 68, 1899-1899.	5.2	0
239	Hypertension, Diabetes, Oxidative Stress, and Cardiovascular Remodeling: Making the Connection with p66shc. , 2008, , 279-291.		0
240	Is heme oxygenase-1 turning out to be a key positive regulator for oxidative stress?. <i>Minerva Medica</i> , 2019, 110, 88-90.	0.9	0
241	Oxidative Stress in Hypertension and Cardiovascular-Renal Remodeling: Focus on the Renin-Angiotensin-Aldosterone System. , 2019, , 581-596.		0
242	Searching for an additional treatment to slowing the progression of Fabry disease. <i>Minerva Medica</i> , 2019, 110, 176-178.	0.9	0
243	Comment on "Vitamin E supplementation improves high-density lipoprotein and endothelial functions in end-stage kidney disease patients undergoing hemodialysis" by Mune et al. <i>Clinical Nephrology</i> DOI 10.5414/CN109197 e-pub: April 9, 2018. <i>Clinical Nephrology</i> , 2019, 91, 323-324.	0.7	0
244	Efficacy of weekly administration of cholecalciferol on parathyroid hormone in stable kidney-transplanted patients with CKD stage 1-3. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 343-351.	2.3	0
245	Massive lung calcifications in a four times renal transplanted patient: the fight against dialysis, hyper and hypoparathyroidism. <i>Minerva Endocrinology</i> , 2021, , .	1.1	0
246	Systemic anticoagulation and new biocompatible dialyzers in the different kidney replacement techniques: More doubts than certainties. <i>Artificial Organs</i> , 2022, 46, 516-517.	1.9	0
247	Double urine circulation: importance of pores. <i>Journal of Nephrology</i> , 2003, 16, 958-60.	2.0	0
248	A Very Unique Case of Boric Acid Intoxication With Very High-magnitude Rhabdomyolysis. <i>Iranian Journal of Kidney Diseases</i> , 2017, 11, 256-257.	0.1	0
249	Molecular aspects of the altered Angiotensin II signalling in Gitelman's syndrome. <i>Expert Opinion on Orphan Drugs</i> , 0, , .	0.8	0
250	MO041: Impaired ACE2 glycosylation and protease activity lowers susceptibility to SARS-COV-2 infection in Gitelman/Bartter syndromes. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
251	MO024: Effect of green tea on top of enzyme replacement therapy in patients with Fabry disease: a molecular biology approach. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0